Published in Breast Cancer Res Treat on January 01, 2005
Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta (2010) 1.32
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene (2014) 1.10
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer (2013) 1.00
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer (2010) 0.89
The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci (2012) 0.87
Lysine methylation promotes VEGFR-2 activation and angiogenesis. Sci Signal (2013) 0.86
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer (2010) 0.86
The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. BMC Cancer (2008) 0.80
Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control (2010) 0.80
Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. Patholog Res Int (2011) 0.78
Biomarkers and the genetics of early neoplastic lesions. Cancer Biomark (2010) 0.78
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs (2013) 0.76
Late recurrence of breast carcinoma metastasis to the hypopharynx: a case report. Springerplus (2016) 0.75
High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer. Mol Clin Oncol (2015) 0.75
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst (2006) 2.71
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2012) 2.24
Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol (2008) 2.17
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
Emergency department triage scales and their components: a systematic review of the scientific evidence. Scand J Trauma Resusc Emerg Med (2011) 1.98
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res (2006) 1.87
Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med (2009) 1.83
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81
Isolation and characterization of progenitor-like cells from human renal proximal tubules. Am J Pathol (2011) 1.72
Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol (2005) 1.66
A systematic review of triage-related interventions to improve patient flow in emergency departments. Scand J Trauma Resusc Emerg Med (2011) 1.63
A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle (2011) 1.60
Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res (2008) 1.59
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res (2003) 1.56
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen (2012) 1.46
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer (2005) 1.45
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene (2005) 1.42
Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res (2005) 1.41
Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev (2010) 1.37
The hip fracture incidence curve is shifting to the right. Acta Orthop (2009) 1.36
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol (2009) 1.34
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res (2005) 1.34
PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer (2010) 1.34
The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene (2002) 1.33
Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer (2011) 1.31
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer (2006) 1.20
The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat (2008) 1.19
Wnt-5a-CKI{alpha} signaling promotes {beta}-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J Biol Chem (2009) 1.18
CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer (2007) 1.17
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology (2003) 1.17
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res (2008) 1.15
Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control (2011) 1.14
Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer (2011) 1.13
A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res (2005) 1.13
Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol (2009) 1.12
Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecol Oncol (2012) 1.11
Prospective study on metabolic factors and risk of prostate cancer. Cancer (2012) 1.09
FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J (2011) 1.09
Hypoxic induction of vascular endothelial growth factor regulates murine hematopoietic stem cell function in the low-oxygenic niche. Blood (2011) 1.08
Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. PLoS One (2009) 1.08
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis (2003) 1.07
Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat (2003) 1.04
Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension (2012) 1.04
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer (2008) 1.03
Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev (2010) 1.03
Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res (2003) 1.02
Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res (2013) 1.02
Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol (2010) 1.02
Genetic predisposition, parity, age at first childbirth and risk for breast cancer. BMC Res Notes (2012) 1.02
Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control (2010) 1.01
High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer (2005) 1.00
PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat (2010) 0.99
Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer (2010) 0.99
Metabolic syndrome and endometrial carcinoma. Am J Epidemiol (2010) 0.99
A novel mutation in the LIM homeobox 3 gene is responsible for combined pituitary hormone deficiency, hearing impairment, and vertebral malformations. J Clin Endocrinol Metab (2009) 0.99
Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study. J Hypertens (2012) 0.98
Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One (2012) 0.98
Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One (2013) 0.98
C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol (2008) 0.97
Increased copy number at 3p14 in breast cancer. Breast Cancer Res (2005) 0.97
Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat (2008) 0.97
Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. Cancer Res (2012) 0.96
Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer (2011) 0.96
Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. PLoS One (2012) 0.95
Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer (2006) 0.95
Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer (2014) 0.95
Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. Int J Cancer (2009) 0.94
Metabolic risk factors and ovarian cancer in the Metabolic Syndrome and Cancer project. Int J Epidemiol (2011) 0.92
Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes Cancer (2010) 0.92
C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med (2005) 0.91
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate (2005) 0.91
Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle (2006) 0.90
Temporal trends in the use of adjuvant systemic therapy in breast cancer: a population based study in Sweden 1976-2005. Acta Oncol (2009) 0.89
Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle (2013) 0.89
Metabolic factors associated with risk of renal cell carcinoma. PLoS One (2013) 0.89
Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer (2007) 0.89
Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations. Epidemiology (2014) 0.89
Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome. Eur J Haematol (2005) 0.89
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res (2010) 0.89
Plant foods and oestrogen receptor alpha- and beta-defined breast cancer: observations from the Malmo Diet and Cancer cohort. Carcinogenesis (2008) 0.89
Pooled cohort study on height and risk of cancer and cancer death. Cancer Causes Control (2013) 0.88
Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells. Oncogene (2004) 0.88
Mortality from myocardial infarction in relation to exposure to vibration and dust among a cohort of iron-ore miners in Sweden. Occup Environ Med (2009) 0.88
Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. J Med Screen (2012) 0.87
Cyclin e overexpression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasion. Cell Cycle (2006) 0.87
Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer (2002) 0.87
p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer (2010) 0.87
Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst (2009) 0.87
Long-term temporal trends in cardiovascular and metabolic risk factors. Wien Klin Wochenschr (2009) 0.87
Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta Oncol (2002) 0.87
Properties of targeted preamplification in DNA and cDNA quantification. Expert Rev Mol Diagn (2015) 0.86